Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
24 results
D1.189 - Does Allergen Immunotherapy Add Clinically Meaningful Benefit in Paediatric Asthma and Allergic Rhinitis? A 36-Month Real-World Comparison
D1.192 - Combined Polymerized Pollen and Animal Dander Immunotherapy Improves Rhinoconjunctivitis and Asthma in Polysensitized Patients: Real-World Evidence
D1.194 - Real-World Effectiveness of Polymerized Dog Allergen Immunotherapy in Allergic Rhinoconjunctivitis and Asthma
D1.186 - Three years treatment with HDM injection allergen immunotherapy, omalizumab, or combination therapy in allergic asthma
D1.198 - Efficacy of Cat Allergen Immunotherapy: A Multicenter Prospective Study
- D1.524 - StingReady: a safe and alternative method for controlled sting challenge tests
- D1.515 - Occupational Exposure of Patients Allergic to Hymenoptera Venom
- D1.516 - Compliance with hymenoptera venom inmunotherapy (VIT)
- D1.517 - Adverse Reactions to Insect Venom Immunotherapy in a Reference Center
- D1.518 - Patient Phenotypes in Prolonged Immunotherapy for Hymenoptera Venom
- D1.519 - Safety of ultra-rush protocols in venom immunotherapy: a systematic review and meta-analysis of Portuguese data
- D1.520 - Immunological modulation during Apis mellifera venom immunotherapy
- D1.522 - Efficacy of hymenoptera venom immunotherapy in Portugal: a systematic review
- D1.523 - Clinical characterization of patients with Hymenoptera venom allergy undergoing venom immunotherapy stratified by basal serum tryptase
- D1.525 - Implementation of allergen-specific immunotherapy for insect allergy
D1.526 - Epidemiologic Characteristics of Hymenoptera Venom Allergic Patients from Two Different Environmental Areas
- D1.527 - Low tryptase and combined IgE biomarkers have limited predictive value in children with severe honeybee venom anaphylaxis
D2.378 - Evaluations of Safety Margins and Response to Deucrictibant Extended-Release (XR) Tablet in Combination with Deucrictibant Immediate-Release (IR) Capsule
D2.367 - Hepatic Involvement and Inflammatory Bowel Disease in Chronic Granulomatous Disease: A Retrospective Evaluation
D2.368 - Concurrent Hereditary Angioedema Type I and Common Variable Immunodeficiency Presenting as Suspected Antibiotic Hypersensitivity: Case Report and Literature Review
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download